Related references
Note: Only part of the references are listed.Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan
Cornelia Meisenberg et al.
NUCLEIC ACIDS RESEARCH (2017)
The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma
Naibin Yang et al.
ONCOTARGET (2017)
Outcomes after repeat hepatic resection for recurrent metastatic colorectal cancer: A population-based study
Sulaiman Nanji et al.
AMERICAN JOURNAL OF SURGERY (2017)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Response Rates of Hepatic Arterial Infusion Pump Therapy in Patients With Metastatic Colorectal Cancer Liver Metastases Refractory to All Standard Chemotherapies
Andrea Cercek et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients
Baohua Lu et al.
THORACIC CANCER (2016)
Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective
Guoli Chen et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progressionfree survival in patients with advanced and/or metastatic colorectal cancer
Wahyu Wulaningsih et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Ken-ichi Fujita et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker
Ming Zhao et al.
PLOS ONE (2015)
Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity
Yuan-Ting Hsieh et al.
PLOS ONE (2015)
CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
Nicola Silvestris et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NF-kappa B
Meiling Yu et al.
MOLECULAR MEDICINE REPORTS (2014)
Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: Associations with clinicopathological and molecular features
Cinzia Azzoni et al.
PATHOLOGY RESEARCH AND PRACTICE (2014)
TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells
Yu-Peng Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A pharmacokinetic evaluation of topotecan as a cervical cancer therapy
Fernanda Musa et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Clinical implications of CES2 RNA expression in neuroblastoma
Keiichi Uchida et al.
JOURNAL OF PEDIATRIC SURGERY (2013)
Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11
M. Jason Hatfield et al.
BIOCHEMICAL PHARMACOLOGY (2011)
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Yves Pommier et al.
CHEMISTRY & BIOLOGY (2010)
Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan (CPT-11)
E. Digkas et al.
FOOD AND CHEMICAL TOXICOLOGY (2010)
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
Miriam Koopman et al.
LANCET (2007)
Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer
K Ohtsuka et al.
LUNG CANCER (2003)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Share Paper
